{"id":"placebo-matched-to-low-dose-cannabidiol","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Changes in appetite"},{"rate":null,"effect":"Somnolence"}]},"_chembl":{"chemblId":"CHEMBL190461","moleculeType":"Small molecule","molecularWeight":"314.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CBD is a non-intoxicating cannabinoid that interacts with CB1 and CB2 receptors, serotonin receptors (5-HT1A), vanilloid receptors (TRPV1), and other targets to exert anti-inflammatory, anxiolytic, and neuroprotective effects. The exact mechanism varies by indication but generally involves modulation of neurotransmitter systems and reduction of neuroinflammation.","oneSentence":"Cannabidiol (CBD) modulates endocannabinoid signaling and multiple receptor systems to produce therapeutic effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:27:50.194Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Indication under investigation in Phase 3 trial (specific indication not specified in provided information)"}]},"trialDetails":[{"nctId":"NCT07123467","phase":"PHASE3","title":"Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder","status":"RECRUITING","sponsor":"Wayne State University","startDate":"2025-11-03","conditions":"Generalized Anxiety Disorder (GAD), Anxiety Disorders","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo Matched to Low-Dose Cannabidiol","genericName":"Placebo Matched to Low-Dose Cannabidiol","companyName":"Wayne State University","companyId":"wayne-state-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cannabidiol (CBD) modulates endocannabinoid signaling and multiple receptor systems to produce therapeutic effects. Used for Indication under investigation in Phase 3 trial (specific indication not specified in provided information).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}